New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Neuroendocrine tumor has long been considered as a rare tumor, although its prevalence makes it one of the most frequent gastrointestinal malignancies . In the eighties, streptozotocin-based chemotherapy allowed substantial improvements in the management of advanced pancreatic neuroendocrine tumors (PNETs) [2, 3]. Subsequently, somatostatin analogues were shown to be useful for the control of symptomatic PNETs and also able to delay tumor progression in slow-growing midgut carcinoids .
Based on large double-blind randomized trials, sunitinib  and everolimus  have been approved last year for the treatment of patients with advanced well-differentiated PNETs. Both drugs significantly improve progression-free survival and provide substantial clinical benefit for patients with advanced PNETs [7, 8]. The availability of those novel drugs is now raising several questions such as the optimal patient management and best possible placement in the current armamentarium of patients with ...
- Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “Carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072 CrossRef
- Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194 CrossRef
- Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523 CrossRef
- Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663 CrossRef
- Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen J-S, Hörsch D, Hammel P, Wiedenmann B, van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513 CrossRef
- Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors Third Trial RADIANT-3 Study Group (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523 CrossRef
- Raymond E, Faivre S, Hammel P, Ruszniewski P (2009) Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol 4:253–254 CrossRef
- Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC (2011) Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934–943 CrossRef
- Teulé A and Casanovas O (2012) Relevance of angiogenesis in neuroendocrine tumors. Target Oncol. doi:10.1007/s11523-012-0217-x
- Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Rusniewski P, Faivre S (2012) Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. doi:10.1007/s11523-012-0220-2
- Benavent M, de Miguel MJ, Garcia-Carbonero R (2012) New targeted agents in gastroenteropancreatic neuroendocrine tumors. Target Oncol. doi:10.1007/s11523-012-0218-9
- Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V (2012) Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol. doi:10.1007/s11523-012-0219-8
- Faivre S et al. (2012) Choi in PNETs. Target Oncol (in press)
- New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Volume 7, Issue 2 , pp 91-92
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Author Affiliations
- 1. Department of Medical Oncology (INSERM U728—Paris 7 Diderot University), Beaujon University Hospital, Assistance Publique—Hôpitaux de Paris, 100 Boulevard du Général Leclerc, Clichy, 92110, France
- 2. Department of Gastro-Entero-Pancreatology, Beaujon University Hospital (Assistance Publique Hopitaux de Paris—Paris 7 Diderot), 100 Boulevard du Général Leclerc, Clichy, 92110, France